Extended β-globin locus control region elements promote consistent therapeutic expression of a γ-globin lentiviral vector in murine β-thalassemia
- 15 October 2004
- journal article
- Published by American Society of Hematology in Blood
- Vol. 104 (8) , 2281-2290
- https://doi.org/10.1182/blood-2004-03-0863
Abstract
Since increased fetal hemoglobin diminishes the severity of β-thalassemia and sickle cell anemia, a strategy using autologous, stem cell–targeted gene transfer of a γ-globin gene may be therapeutically useful. We previously found that a γ-globin lentiviral vector utilizing the β-globin promoter and elements from the β-globin locus control region (LCR) totaling 1.7 kb could correct murine β-thalassemia. However, therapeutic consistency was compromised by chromosomal position effects on vector expression. In contrast, we show here that the majority of animals that received transplants of β-thalassemic stem cells transduced with a new vector containing 3.2 kb of LCR sequences expressed high levels of fetal hemoglobin (17%-33%), with an average vector copy number of 1.3. This led to a mean 26 g/L (2.6 g/dL) increase in hemoglobin concentration and enhanced amelioration of other hematologic parameters. Analysis of clonal erythroid cells of secondary spleen colonies from mice that underwent transplantation demonstrated an increased resistance of the larger LCR vector to stable and variegating position effects. This trend was also observed for vector insertion sites located inside genes, where vector expression was often compromised, in contrast to intergenic sites, where higher levels of expression were observed. These data emphasize the importance of overcoming detrimental position effects for consistent therapeutic globin vector expression.Keywords
This publication has 36 references indexed in Scilit:
- Correction of a mouse model of sickle cell disease: lentiviral/antisickling β-globin gene transduction of unmobilized, purified hematopoietic stem cellsBlood, 2003
- Chimerism and cure: hematologic and pathologic correction of murine sickle cell diseaseBlood, 2003
- A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human β-globin gene transferBlood, 2003
- Side effects of retroviral gene transfer into hematopoietic stem cellsBlood, 2003
- The degree of phenotypic correction of murine β-thalassemia intermedia following lentiviral-mediated transfer of a human γ-globin gene is influenced by chromosomal position effects and vector copy numberBlood, 2003
- High-Level Erythroid Lineage-Directed Gene Expression Using Globin Gene Regulatory Elements After Lentiviral Vector-Mediated Gene Transfer into Primitive Human and Murine Hematopoietic CellsHuman Gene Therapy, 2002
- Permanent and panerythroid correction of murine β thalassemia by multiple lentiviral integration in hematopoietic stem cellsProceedings of the National Academy of Sciences, 2002
- Correction of Sickle Cell Disease in Transgenic Mouse Models by Gene TherapyScience, 2001
- Functional requirements for phenotypic correction of murine β-thalassemia: implications for human gene therapyBlood, 2001
- Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globinNature, 2000